L. Michael Glodé, MD, FACP, Professor Emeritus at the University of Colorado Cancer Center and a medical oncologist at the Shaw Regional Cancer Center in Edwards, Colorado, discusses the mechanism of action of the TMPRSS2 and ACE2 pathways, and their relationship to the host-cell entry of COVID-19. He goes on to discuss a clinical trial using the serine protease inhibitor Camostat, noting how 5ARIs and GNRH analogues could act as a target for prevention and possible treatment of COVID-19. He also discusses the results of an Italian observational study which demonstrated how prostate cancer patients receiving ADT appear to be partially protected from COVID-19 infection.Read More
L. Michael Glodé, MD, FACP
University of Colorado Cancer Center
Dr. Glodé is Professor Emeritus of Medical Oncology and the former Robert Rifkin Chair for Prostate Cancer Research at the University of Colorado Cancer Center in Aurora, Colorado. He was the first board-certified medical oncologist at the University of Colorado, joining the faculty after training at the Dana-Farber Cancer Institute in Boston. Dr. Glodé’s research has been clinically focused on prostate cancer for many years. He headed the initial research on leuprolide, leading to its approval. He has also led efforts to evaluate a natural product, silibinin, as a preventive or therapeutic agent. He has been an investigator on more than 30 clinical trials, including the PI position for one of the largest adjuvant trials in prostate cancer, SWOG 9921. Dr. Glodé has received numerous teaching awards and founded the AACR course “Molecular Biology for Clinical Oncologists.” He has also served as Founding Editor of the ASCO website, as well as Chair of ASCO’s Integrated Media and Technology and Cancer Education Committees. He is the author of prost8blog, a blog intended to help prostate cancer patients and their families.
Articles by L. Michael Glodé, MD, FACP
Posted by L. Michael Glodé, MD, FACP | Apr 2018
L. Michael Glode, MD, FACP, FASCO, discusses the mechanism of action of PARP, the basic science behind Synthetic Lethal mutations, clinical trials for PARP inhibition in prostate cancer, and the importance of testing for DNA repair mutations.Read More